Generic Name: Vinblastine Sulfate
Class: Antineoplastic Agents
VA Class: AN900
CAS Number: 143-67-9
- Administration Warnings
For IV use only.127
Fatal if given intrathecally.127 (See Intrathecal Administration under Cautions.)
Extremely important to properly place IV needle or catheter securely within vein before vinblastine is injected.127
Leakage into surrounding tissues may cause considerable irritation.127
Discontinue immediately if leakage occurs; administer remainder of the dose through another vein.127 b
Local treatment of leakage area (e.g., with hyaluronidase injection, application of moderate heat) may help disperse vinblastine and minimize discomfort and possibility of cellulitis.127
Introduction
Antineoplastic agent; vinca alkaloid.134 139
Uses for Velban
Hodgkin’s Disease
In combination chemotherapy as first- or second-line therapy for Hodgkin’s disease.127 135
Often used with doxorubicin, bleomycin, and dacarbazine (known as the ABVD regimen) as first-line therapy for Hodgkin’s disease.135 138
Under investigated in other combination regimens (e.g., Stanford V regimen: doxorubicin, bleomycin, vinblastine, vincristine, mechlorethamine, etoposide, and prednisone) for the treatment of advanced Hodgkin's disease.135 138
Testicular Cancer
For the treatment of advanced nonseminomatous testicular carcinoma, combination chemotherapy regimens containing vinblastine, cisplatin, and bleomycin have been used;127 128 129 130 however, most clinicians recommend regimens containing cisplatin and bleomycin, in combination with etoposide rather than vinblastine, as first-line therapy, particularly because of the reduced risk of neuromuscular toxicity and evidence suggesting greater efficacy in poor-risk patients.128 129 130 135
A regimen of cisplatin, ifosfamide, and either vinblastine or etoposide currently is considered by most clinicians to be the standard initial salvage (i.e., second-line) regimen in patients with recurrent testicular cancer.128 135
AIDS-related Kaposi’s Sarcoma
Has been used alone135 140 141 or in combination140 142 143 144 145 146 chemotherapy for the palliative treatment of AIDS-related Kaposi’s sarcoma.
Single-agent therapy with vinblastine is considered an alternative regimen.135
Combination chemotherapy with a vinca alkaloid (vinblastine or vincristine) also has been a preferred regimen,135 140 145 146 but many clinicians currently consider a liposomal anthracycline (doxorubicin or daunorubicin) the first-line therapy of choice for advanced AIDS-related Kaposi’s sarcoma.135 140 180 193 199
Combination chemotherapy with conventional antineoplastic agents (e.g., bleomycin, conventional doxorubicin, etoposide, vinblastine, vincristine) has been used for more advanced disease (e.g., extensive mucocutaneous disease, lymphedema, symptomatic visceral disease).140 145 146 182 194
A liposomal anthracycline for the treatment of advanced AIDS-related Kaposi’s sarcoma produces similar or higher response rates with a more favorable toxic effects profile than combination therapy with conventional chemotherapeutic agents.140 180 193 199
Classic Kaposi’s Sarcoma
Single-agent vinblastine has been used for the treatment of classic Kaposi's sarcoma.127 140
Bladder Cancer
In combination regimens with cisplatin and methotrexate, with or without doxorubicin, as first- or second-line therapy for invasive and advanced bladder cancer†.135 188 189 190 191
Non-small Cell Lung Cancer
In combination with cisplatin and mitomycin (MVP)126 as an alternative regimen for the treatment of non-small cell lung cancer†.135 192
Currently preferred regimens for the treatment of advanced non-small cell lung cancer include the combination of cisplatin or carboplatin, with another agent, such as paclitaxel, docetaxel, vinorelbine, or gemcitabine.135 192
Melanoma
Used in combination regimens (e.g., cisplatin, vinblastine, and dacarbazine, with or without interferon alfa and aldesleukin) for the treatment of metastatic melanoma†.135 216 218 219
Superiority of combination regimens compared with dacarbazine alone not established,212 215 217 and dacarbazine monotherapy currently is a systemic treatment of choice for metastatic melanoma.135 213 214 215 217
Brain Tumors
In combination with cisplatin and bleomycin or as monotherapy (second-line) for the treatment of intracranial germ cell tumors†.135 187
Immune Thrombocytopenic Purpura
Has been used in the treatment of immune thrombocytopenic purpura†.224
Autoimmune Hemolytic Anemia
Slow IV infusions of vinblastine106 or the use of vinblastine-loaded platelets107 108 has reportedly been effective in some cases for the treatment of autoimmune hemolytic anemia†.106 107 108
Non-Hodgkin’s Lymphoma
Palliative treatment of non-Hodgkin’s lymphomas, including lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated), histiocytic lymphoma, and advanced stages of mycosis fungoides;127 however, other agents currently are preferred.135
Letterer-Siwe Disease
Treatment of Letterer-Siwe disease.127
Velban Dosage and Administration
General
Consult specialized references for procedures for proper handling and disposal of antineoplastics.127
Care must be taken to avoid contact with the eyes as severe irritation and possibly corneal ulceration (especially if administered under pressure) can result; if contact occurs, immediately wash eyes thoroughly.127
Administration of antiemetics may easily control nausea and vomiting.127 b
Administration
For solution and drug compatibility information, see Compatibility under Stability.
IV Administration
Administer IV only by individuals experienced in the administration of the drug.127
Very irritating; must not be given IM, sub-Q, or intrathecally.127 Intrathecal administration usually results in death.127 (See Boxed Warning.)
Management of patients mistakenly receiving intrathecal vinblastine is a medical emergency.127 If administered intrathecally, immediate neurosurgical intervention is required to prevent ascending paralysis leading to death.127 (See Intrathecal Administration under Cautions.)
Administer appropriate quantity of commercially available or reconstituted solution by IV injection into the tubing of a running IV infusion or directly into a vein.127 b
Because of the enhanced possibility of thrombosis, do not inject into an extremity with impaired or potentially impaired circulation caused by compression or invading neoplasm, phlebitis, or varicosity.127 b
Because of possible leukopenic response, administer at intervals of at least 7 days;127 however, even if 7 days have elapsed, do not give next dose until leukocyte count has returned to ≥4000/mm3.127 Strict adherence to recommended dosage interval is important.b
To ensure an adequate trial, therapy must be continued for at least 4–6 weeks.b Some experts advocate a trial of at least 12 weeks, particularly in patients with carcinomas.b
Extravasation
Extremely important to ensure that the needle or catheter is securely within the vein in order to avoid extravasation.127
The manufacturers recommend rinsing the syringe and needle with venous blood after administration of the drug and before withdrawal of the needle to further minimize the possibility of extravasation.127 b
If leakage occurs, discontinue injection immediately and administer remainder of the dose through another vein; local treatment of the area of leakage may minimize discomfort and the possibility of cellulitis.b (See Boxed Warning and also see Local Effects under Cautions.)
Reconstitution
Reconstitute powder for injection by adding 10 mL of bacteriostatic sodium chloride injection containing benzyl alcohol as a preservative or 10 mL of sodium chloride injection (without preservatives) to a vial labeled as containing 10 mg of the drug to provide a solution containing 1 mg/mL.127
Do not use other diluents; do not combine with any other chemical.127
Dilution
To minimize the risk of extravasation and/or venous irritation, do not dilute in large volumes of IV solution (e.g., 100–250 mL).127
Rate of Administration
Inject appropriate quantity of commercially available or reconstituted solution into the tubing of a running IV infusion or directly into a vein over about a 1-minute period.b
To minimize risk of extravasation and/or venous irritation, do not infuse over long periods of time (i.e., from 30–60 minutes or longer).127
Dispensing Precautions
When dispensing, must label syringe or container holding the individual dose with the statement: “Warning: Fatal if given intrathecally. For intravenous use only.”127
Enclose container or syringe holding the individual dose in an overwrap (e.g., plastic bag or similar wrap with typed label) bearing the statements: “Do not remove covering until moment of injection. Fatal if given intrathecally. For intravenous use only.”127 (See Intrathecal Administration under Cautions.)
Consider additional measures to prevent inadvertent intrathecal administration, including: administering diluted vinblastine solutions in minibags; preparing the medication at the time of administration; attaching a unique filter; dispensing separately from all other medications; dispensing directly to the individual who is administering the drug; conducting an independent check of the dose and route of administration for the drug both at the time of preparation and prior to administration; and administering vinblastine in a separate room from rooms where intrathecal medications are administered.225
Dosage
Available as vinblastine sulfate; dosage expressed in terms of the salt.127
Dosage varies depending on the schedule used and whether vinblastine is administered as a single agent or incorporated within a particular chemotherapeutic regimen.127 Consult published protocols for dosages in combination regimens.b
Use of small daily doses for prolonged periods (even if equivalent to the total weekly dosage) is not recommended because it has produced severe toxicity with little or no added therapeutic benefit.b
Pediatric Patients
General Dosage
Some evidence indicates that the usual initial pediatric dosage varies depending on the schedule used and whether vinblastine is administered as a single agent or incorporated within a particular chemotherapeutic regimen.127
Hodgkin’s Disease
IV
In combination with other chemotherapeutic agents, an initial dosage of 6 mg/m2 has been used.127 Adjust dosage based on hematologic tolerance.127 Consult published protocols for additional information on dosage.
Testicular Germ Cell Carcinoma
IV
An initial dosage of 3 mg/m2 has been used in a combination regimen.127 Adjust dosage based on hematologic tolerance.127 Consult published protocols for additional information on dosage.
Letterer-Siwe Disease
IV
As monotherapy, an initial dosage of 6.5 mg/m2 reportedly has been used.127 Adjust dosage based on hematologic tolerance.127 Consult published protocols for additional information on dosage.
Adults
General Dosage
Initial Dosage
IV
Initially, 3.7 mg/m2 given as a single dose.127
Dosage Modification
Determine subsequent dosage by clinical and hematologic response and patient tolerance to obtain optimum therapeutic results with minimum adverse effects.127
Increase dosage at weekly intervals in increments of about 1.8–1.9 mg/m2 until desired therapeutic response is obtained, the leukocyte count decreases to about 3000/mm3, or a maximum weekly dose of 18.5 mg/m2 is reached.127
In most adults, the optimum weekly dose will be 5.5–7.4 mg/m2; however, leukopenia (leukocyte count of 3000/mm3) may occur in some patients with 3.7 mg/m2 per week, whereas other patients may tolerate 11.1–18.5 mg/m2 per week.127
Once the dose required to produce a leukocyte count of 3000/mm3 has been determined, administer a maintenance dose of one increment (1.8 mg/m2) less than this amount (e.g., the maximum dose that does not cause leukopenia) at weekly intervals.127
Dosage generally is reduced in patients with recent exposure to radiation therapy or chemotherapy; single doses in these patients usually do not exceed 5.5 mg/m2.b
Maintenance Dosage
Duration of maintenance therapy varies according to disease being treated and combination of chemotherapeutic agents being used; there are differences of opinion regarding duration of maintenance therapy with the same protocol for a particular disease.127
Prolonged chemotherapy for maintaining remissions involves several risks (i.e., life-threatening infectious diseases, sterility, possible appearance of other neoplasms resulting from immune system suppression).127
In some disorders, survival following complete remission may not be as prolonged as that achieved with shorter periods of maintenance therapy; however, failure to provide maintenance therapy in some patients may lead to unnecessary relapse.127
Prescribing Limits
Adults
IV
Maximum 18.5 mg/m2 weekly.127
Special Populations
Hepatic Impairment
In patients with a direct serum bilirubin >3 mg/dL, dosage reduction of 50% recommended.127
Renal Impairment
No dosage reduction recommended.127
Cautions for Velban
Contraindications
Warnings/Precautions
Warnings
Intrathecal Administration
Fatal if administered intrathecally; immediate neurosurgical intervention required to prevent ascending paralysis leading to death.127
Prognosis to date (principally with patients inadvertently administered vincristine intrathecally) generally has been poor despite immediate efforts to remove spinal fluid and flush with lactated Ringer's injection, with such efforts failing to prevent ascending paralysis and death in almost all cases.133
In a very small number of patients, life-threatening paralysis and subsequent death have been averted, but devastating neurologic sequelae, with limited recovery afterwards, have resulted.127
There are no published cases of survival following intrathecal administration of vinblastine to use as guidance for treatment.127
According to published reports of survivors of inadvertent intrathecal administration of vincristine, treatment consists of immediate removal of as much CSF as safely possible via lumbar access, followed by insertion of an epidural catheter into the subarachnoid space via the intervertebral space above initial lumbar access and then CSF irrigation with lactated Ringer’s solution; add fresh frozen plasma (25 mL) to every L of lactated Ringer’s solution when available.127
Insert intraventricular drain or catheter (by a neurosurgeon), continue CSF irrigation with fluid removal through the lumbar access connected to a closed drainage system.127 Give lactated Ringer’s solution by continuous infusion at the rate of 150 mL/hour, or at a rate of 75 mL/hour when fresh frozen plasma has been added.127 Adjust rate to maintain CSF protein concentration of 150 mg/dL.127
Additional measures have been used but may not be essential, including glutamic acid (10 g IV over 24 hours, followed by 500 mg orally 3 times daily for 1 month), leucovorin (100-mg IV bolus followed by an infusion of 25 mg/hour for 24 hours, then 25 mg by IV bolus every 6 hours for 1 week), or pyridoxine hydrochloride (50 mg has been administered as an IV infusion over 30 minutes every 8 hours).127 133 The contribution of these additional therapies to reduction of neurotoxicity is unclear.127
Hematologic Effects
Leukopenia occurs commonly and is usually the dose-limiting factor in therapy.127 b Nadir in leukocyte count generally occurs 5–10 days after administration and recovery usually occurs within another 7–14 days;127 however, following administration of high doses, recovery may take ≥21 days.b
Perform blood counts weekly or at least before administration of each dose.127 b
If leukopenia with <2000/mm3 occurs following a dose, carefully monitor patient for signs of infection.127
More profound leukopenia possible in patients with cachexia or ulcerated areas of skin; avoid use in patients (especially geriatric patients) with these conditions.127
In patients with malignant-cell infiltration of the bone marrow, an abrupt decrease in leukocyte and platelet counts may occur after moderate doses;127 manufacturers recommend discontinuance in such patients,127 but many clinicians consider it appropriate to continue therapy if the drug is clearly destroying tumor cells in the bone marrow.b
Anemia also may occur.b
Patients who receive myelosuppressive drugs experience an increased frequency of infections as well as possible hemorrhagic complications.b
Nervous System Effects
Possible neurotoxicity, sometimes disabling;127 occurs occasionally in patients receiving vinblastine, especially with high doses or prolonged therapy, but less frequently than with vincristine therapy.b
When doses several times the recommended weekly dosage were administered daily for long periods, seizures, permanent CNS damage, and death occurred;127 however, some clinicians believe that patients with rapidly progressing tumors with short generation times should receive large divided doses over several days, repeated as often as toxicity permits.b
GI Effects
Possible stomatitis; although reversible, can be disabling.127
GI symptoms, particularly constipation, abdominal pain, and adynamic ileus, may be related to neurotoxicity.b
Fetal/Neonatal Morbidity and Mortality
May cause fetal harm; teratogenicity demonstrated in animals.127 Avoid pregnancy during therapy.127 If used during pregnancy or patient becomes pregnant, apprise of potential fetal hazard.127
Genitourinary Effects
Aspermia reported during therapy; reproductive studies in animals have revealed evidence of metaphase arrest and degenerative changes in germ cells.127
General Precautions
Highly toxic drug with low therapeutic index; therapeutic response is not likely to occur without some evidence of toxicity.b Administer only under constant supervision by clinicians experienced in therapy with cytotoxic agents.b
Respiratory Effects
Acute shortness of breath and bronchospasm, which can be severe or life threatening, have occurred; reported most frequently when mitomycin was administered concomitantly.127
Such reactions may occur a few minutes to several hours after administration of a vinca alkaloid, or up to 2 weeks after mitomycin dose.127
Aggressive treatment may be required, particularly in patients with preexisting pulmonary dysfunction.127
Progressive dyspnea, which may require chronic therapy, can occur in patients receiving vinblastine; do not readminister to these patients.127
Patients with preexisting pulmonary dysfunction may be particularly susceptible to severe or life-threatening pulmonary effects.127
Cardiovascular Effects
Caution is advised when using vinblastine in patients with ischemic cardiovascular disease, and care of this condition should be recommended.127
Hypertension is the most common adverse cardiovascular effect of vinblastine.127
Cases of unexpected MI and cerebrovascular accident reported in patients receiving vinblastine in combination with bleomycin and cisplatin.127 223
Raynaud's phenomenon reported in patients receiving vinblastine and bleomycin, with or without cisplatin.127
Local Effects
Tissue irritant; may cause phlebitis and necrosis.127 b Extravasation can result in pain and cellulitis.127 b
If extravasation of large amounts of the injection occurs, sloughing may result; local reactions may be severe and can persist for several weeks to months.b
Manufacturers state that local injection of hyaluronidase and application of moderate heat may decrease local reactions resulting from extravasation;127 however, some clinicians prefer to treat extravasation with cold compresses, dilution with 0.9% sodium chloride injection, and/or local injection of hydrocortisone.b
Otic Effects
Eighth cranial nerve damage, which may be evident as vestibular manifestations (e.g., dizziness, nystagmus, vertigo) and by auditory manifestations (e.g., varying degrees of hearing impairment) that may be temporary or permanent, reported in patients receiving vinca alkaloids.127
Use vinca alkaloids concomitantly with other potentially ototoxic drugs (e.g., platinum-containing antineoplastic agents) with extreme caution.127 (See Specific Drugs under Interactions.)
Hyperuricemia
Hyperuricemia may result from extensive purine catabolism accompanying rapid cellular destruction in some patients receiving vinblastine, especially those with non-Hodgkin’s lymphomas or leukemia.b
In some patients, uric acid nephropathy may result.b
Minimize by adequate hydration, alkalinization of the urine, and/or administration of allopurinol.b
Dermatologic Effects
Vinblastine-induced alopecia is common; other adverse dermatologic effects occur infrequently following vinblastine therapy and include dermatitis and vesiculation of the skin, phototoxicity, and epilation.b
Epilation is partial and almost always reversible; in some cases, hair may regrow during maintenance therapy.b
Specific Populations
Pregnancy
Category D.pdh 127 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)
Lactation
Not known whether vinblastine is distributed in milk.127 Discontinue nursing or the drug.127
Geriatric Use
Avoid use in geriatric patients with cachexia or ulcerated areas of skin; more profound leukopenia is possible in such patients.127
Hepatic Impairment
In patients with hepatic impairment, toxicity may be enhanced.127 Caution advised.127 (See Hepatic Impairment under Dosage and Administration.)
Common Adverse Effects
Leukopenia, alopecia, constipation, nausea, vomiting, hypertension, malaise, bone pain, pain in tumor-containing tissue, jaw pain, paresthesia, peripheral neuropathy and neuritis, numbness, loss of deep tendon reflexes, muscle pain and weakness, ileus, anorexia, stomatitis, weight loss, anemia.127 b pdh
Interactions for Velban
Metabolized by CYP3A.127 185
Drugs Affecting Hepatic Microsomal Enzymes
Inhibitors of CYP3A: potential pharmacokinetic interaction (inhibition of vinblastine metabolism); earlier onset and/or increased severity of adverse effects of vinblastine may occur.127 Use concomitantly with caution.127 185
Ototoxic Drugs
Since varying degrees of permanent or temporary hearing impairment associated with eighth cranial nerve damage have been reported in patients receiving vinca alkaloids, use concomitantly with other potentially ototoxic drugs with extreme caution.127 (See Specific Drugs under Interactions.)
Specific Drugs
Drug
|
Interaction
|
Comments
|
|---|
Antifungals, azoles
|
Itraconazole: Earlier onset and/or increased severity of neuromuscular effects reported with another vinca alkaloid (vincristine)184 185
Voriconazole: Possible neurotoxicity220
|
Monitor patients receiving a vinca alkaloid and an azole antifungal for increases in and/or prolongation of the effects of vinca alkaloids, including adverse effects (e.g., peripheral neuropathy, ileus); adjust dosage of the vinca alkaloid appropriately186 220
|
Aprepitant
|
Possible pharmacokinetic interaction221
|
Caution advised; monitor carefully221
|
Erythromycin
|
Increased vinblastine toxicity reported127
|
|
Ototoxic drugs (e.g., platinum-containing antineoplastic agents)
|
Potential additive ototoxic effect127
|
Varying degrees of permanent or temporary hearing impairment associated with eighth cranial nerve damage reported in patients receiving vinca alkaloids; use concomitantly with other potentially ototoxic drugs with extreme caution127
|
Phenytoin
|
Decreased serum concentrations of phenytoin and increased seizure activity reported127 131
|
Contribution of vinblastine to interaction is uncertain127
In patients receiving phenytoin and vinblastine concomitantly, monitor serum phenytoin concentrations and adjust dosage as necessary127 131
|
Tolterodine
|
Possible increased tolterodine concentrations222
|
Reduce tolterodine dosage to 50% of the recommended dosage222
|
Velban Pharmacokinetics
Absorption
Bioavailability
Unpredictably absorbed from the GI tract.b
Distribution
Extent
Following IV administration, rapidly cleared from the blood and distributed into body tissues.b Crosses the blood-brain barrier poorly and does not appear in the CSF in therapeutic concentrations.b
Elimination
Metabolism
Reported to be extensively metabolized, mainly in the liver, to desacetylvinblastine, which is more active than the parent compound on a weight basis.b 127
Mediated by CYP3A.127
Elimination Route
Excreted slowly in urine and in feces via bile.b
Special Populations
Metabolism via CYP isoenzymes may be impaired in patients with hepatic dysfunction.127
Stability
Storage
Parenteral
Injection
2–8°C.b Protect from light.b
Powder for Injection
Store vials at 2–8°C to assure extended stability.127 Protect from light.b
After reconstitution with bacteriostatic sodium chloride injection (preserved with benzyl alcohol), solutions are stable for 28 days when refrigerated at 2–8°C.127
When reconstituted with a diluent that does not contain a preservative, discard any unused portions immediately.127
Compatibility
For information on systemic interactions resulting from concomitant use, see Interactions.
Parenteral
Solution CompatibilityHID
Compatible
|
|---|
Dextrose 5% in water
|
Ringer’s injection, lactated
|
Sodium chloride 0.9%
|
Drug Compatibility
Admixture CompatibilityHID
Compatible
|
|---|
Bleomycin sulfate
|
Variable
|
|---|
Doxorubicin HCl
|
Y-Site CompatibilityHID
Compatible
|
|---|
Allopurinol sodium
|
Amifostine
|
Amphotericin B cholesteryl sulfate complex
|
Aztreonam
|
Bleomycin sulfate
|
Cisplatin
|
Cyclophosphamide
|
Doxorubicin HCl
|
Doxorubicin HCl liposome injection
|
Droperidol
|
Etoposide phosphate
|
Filgrastim
|
Fludarabine phosphate
|
Fluorouracil
|
Gemcitabine HCl
|
Granisetron HCl
|
Heparin sodium
|
Leucovorin calcium
|
Melphalan HCl
|
Methotrexate sodium
|
Metoclopramide HCl
|
Mitomycin HCl
|
Ondansetron HCl
|
Paclitaxel
|
Pemetrexed disodium
|
Piperacillin sodium–tazobactam sodium
|
Sargramostim
|
Teniposide
|
Thiotepa
|
Vincristine sulfate
|
Vinorelbine tartrate
|
Incompatible
|
|---|
Cefepime HCl
|
Furosemide
|
Lansoprazole
|
ActionsActions
Mechanism of action not fully elucidated; vinblastine and other vinca alkaloids exert their cytotoxic effects by binding to tubulin, the protein subunit of the microtubules that form the mitotic spindle.134 139
Formation of vinblastine-tubulin complexes prevents the polymerization of the tubulin subunits into microtubules and induces depolymerization of microtubules resulting in inhibition of microtubule assembly and cellular metaphase arrest.134
In high concentrations, also exerts complex effects on nucleic acid and protein synthesis.b
Also interferes with amino acid metabolism by blocking cellular utilization of glutamic acid and thus inhibits purine synthesis, the citric acid cycle, and the formation of urea.b
Exerts some immunosuppressive activity.b
Advice to Patients
Importance of notifying a clinician if fever, sore throat, unusual bleeding or bruising, or any other serious adverse event occurs.127 b
Advise patients regarding avoidance of constipation.127
Advise patients that alopecia may occur, but that scalp hair may regrow to its pretreatment extent even with continued therapy.127
Advise patients that jaw pain and pain in the organs containing tumor tissue (possibly resulting from swelling of tumor tissue during treatment response) may occur.127
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses.b
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.b
Importance of informing patients of other important precautionary information.127 (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Vinblastine Sulfate
Routes
|
Dosage Forms
|
Strengths
|
Brand Names
|
Manufacturer
|
|---|
Parenteral
|
Injection, for IV use only
|
1 mg/mL*
|
Vinblastine Sulfate Injection
|
|
|
For injection, for IV use only
|
10 mg*
|
Vinblastine Sulfate for Injection
|
|
Disclaimer
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions April 2009. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
References
Only references cited for selected revisions after 1984 are available electronically.
100. Marmot AM, Damasio EE, Gori E. Vinblastine sulfate in idiopathic thrombocytopenic purpura. Lancet. 1971; 2:94. [IDIS 18500] [PubMed 4104002]
101. Sultan Y, Delobel J, Jeanneau C et al. Effect of periwinkle alkaloids in idiopathic thrombocytopenic purpura. Lancet. 1971; 1:496-7. [IDIS 19439] [PubMed 4100368]
102. Rodgers GM, Ries CA. Refractory idiopathic thrombocytopenic purpura. Ann Intern Med. 1980; 92:713-4.
103. Ahn YS, Harrington WJ, Mylvaganam R et al. Slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura. Ann Intern Med. 1984; 100:192-6. [IDIS 181312] [PubMed 6537881]
104. Ahn YS, Byrnes JJ, Harrington WJ et al. The treatment of idiopathic thrombocytopenia with vinblastine-loaded platelets. N Engl J Med. 1978; 298:1101-7. [PubMed 565464]
105. Rosse WF. Whatever happened to vinca-loaded platelets? N Engl J Med. 1984; 310:1051-2. Editorial.
106. Medellin PL, Patten E, Weiss GB. Vinblastine for autoimmune hemolytic anemia. Ann Intern Med. 1982; 96:123. [IDIS 142633] [PubMed 7053689]
107. Gertz MA, Petitt RM, Pineda AA et al. Vinblastine-loaded platelets for autoimmune hemolytic anemia. Ann Intern Med. 1981; 95:325-6. [IDIS 137107] [PubMed 7271094]
108. Ahn YS, Harrington WJ, Byrnes JJ et al. Treatment of autoimmune hemolytic anemia with vinca-loaded platelets. JAMA. 1983; 249:2189-94. [PubMed 6834615]
109. Dyke RW. Acute bronchospasm after a vinca alkaloid in patients previously treated with mitomycin. N Engl J Med. 1984; 310:389. [IDIS 181096] [PubMed 6690968]
126. Veeder MH, Jett JR, Su JQ et al. A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer. 1992; 70:2281-7. [IDIS 304727] [PubMed 1394057]
127. Bedford Laboratories. Vinblastine sulfate for injection prescribing information. Bedford, OH; Dec 2001.
128. Testicular cancer. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2007 May.
129. Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987; 316:1435-40. [IDIS 231286] [PubMed 2437455]
130. Loehrer PJ, Williams SD, Einhorn LH. Testicular cancer: the quest continues. J Natl Cancer Inst. 1988; 80:1373-83. [PubMed 3050140]
131. Hydantoins/antineoplastic agents. In: Tatro DS, Olin BR, Hebel SK eds. Drug interaction facts. St. Louis; JB Lippincott Co; 1991 Apr:373.
133. Dyke RW. Treatment of inadvertent intrathecal injection of vincristine. N Engl J Med. 1989; 321:1270-1. [IDIS 260603] [PubMed 2797094]
134. Zhou XJ, Rahmani R. Preclinical and clinical pharmacology of vinca alkaloids. Drugs. 1992; 44(Suppl 4):1-16. [PubMed 1283846]
135. Anon. Drugs of choice for cancer. Treat Guidel Med Lett. 2003; 1:41-52. [PubMed 15529105]
136. Urba WJ, Longo DL. Hodgkin’s disease. N Engl J Med. 1992; 326:678-687. [IDIS 292239] [PubMed 1736106]
137. DeVita VT Jr, Hubbard SM. Hodgkin’s disease. N Engl J Med. 1993; 328:560-565. [IDIS 309839] [PubMed 8426624]
138. Adult Hodgkin’s lymphoma. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2007 May 3.
139. Rowinsky EK, Donehower RC. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther. 1991; 52:35-84. [PubMed 1687171]
140. Kaposi’s sarcoma. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2006 Dec 13.
141. Volberding PA, Abrams DI, Conant M et al. Vinblastine therapy for Kaposi’s sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med. 1985; 103:335-8. [IDIS 205816] [PubMed 4026082]
142. Kaplan L, Abrams D, Volberding P. Treatment of Kaposi’s sarcoma in acquired immunodeficiency syndrome with an alternating vincristine-vinblastine regimen. Cancer Treat Rep. 1986; 70:1121-2. [IDIS 222400] [PubMed 3742492]
143. Laubenstein LJ, Krigel RL, Odajnyk CM et al. Treatment of epidemic Kaposi’s sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol. 1984; 2:1115-20. [PubMed 6208343]
144. Gelmann EP, Longo D, Lane HC et al
